Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Kymera Therapeutics Inc (NASDAQ: KYMR) was $73.46 for the day, up 1.45% from the previous closing price of $72.41. In other words, the price has increased by $1.45 from its previous closing price. On the day, 1.0 million shares were traded. KYMR stock price reached its highest trading level at $73.815 during the session, while it also had its lowest trading level at $69.08.
Ratios:
Our analysis of KYMR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
B. Riley Securities reiterated its Buy rating for the stock on October 24, 2025, while the target price for the stock was revised from $60 to $80.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 31 ’25 when Mainolfi Nello sold 30,000 shares for $78.06 per share. The transaction valued at 2,341,939 led to the insider holds 663,077 shares of the business.
Mainolfi Nello bought 30,000 shares of KYMR for $2,330,700 on Dec 31 ’25. On Dec 17 ’25, another insider, Esposito Pamela, who serves as the Director of the company, sold 27,563 shares for $82.16 each. As a result, the insider received 2,264,480 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 5876728320 and an Enterprise Value of 4863690752. For the stock, the TTM Price-to-Sale (P/S) ratio is 132.62 while its Price-to-Book (P/B) ratio in mrq is 5.57. Its current Enterprise Value per Revenue stands at 111.208 whereas that against EBITDA is -15.126.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.22, which has changed by 0.7870188 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $103.00, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 3.37%, while the 200-Day Moving Average is calculated to be 50.27%.
Shares Statistics:
KYMR traded an average of 936.01K shares per day over the past three months and 740580 shares per day over the past ten days. A total of 71.74M shares are outstanding, with a floating share count of 65.71M. Insiders hold about 16.77% of the company’s shares, while institutions hold 91.58% stake in the company. Shares short for KYMR as of 1765756800 were 7894340 with a Short Ratio of 8.43, compared to 1763078400 on 8581283. Therefore, it implies a Short% of Shares Outstanding of 7894340 and a Short% of Float of 11.88.
Earnings Estimates
The performance of Kymera Therapeutics Inc (KYMR) in the stock market is under the watchful eye of 20.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.76 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$2.77 and -$3.86 for the fiscal current year, implying an average EPS of -$3.46. EPS for the following year is -$3.71, with 21.0 analysts recommending between -$2.99 and -$6.01.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 21 analysts. It ranges from a high estimate of $52.24M to a low estimate of $3M. As of. The current estimate, Kymera Therapeutics Inc’s year-ago sales were $7.39MFor the next quarter, 21 analysts are estimating revenue of $10.62M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.
A total of 22 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $105M, while the lowest revenue estimate was $39.1M, resulting in an average revenue estimate of $53.36M. In the same quarter a year ago, actual revenue was $47.07MBased on 22 analysts’ estimates, the company’s revenue will be $47.38M in the next fiscal year. The high estimate is $100M and the low estimate is $10M.
